Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells.
Haas AR, Golden RJ, Litzky LA, Engels B, Zhao L, Xu F, Taraszka JA, Ramones M, Granda B, Chang WJ, Jadlowsky J, Shea KM, Runkle A, Chew A, Dowd E, Gonzalez V, Chen F, Liu X, Fang C, Jiang S, Davis MM, Sheppard NC, Zhao Y, Fraietta JA, Lacey SF, Plesa G, Melenhorst JJ, Mansfield K, Brogdon JL, Young RM, Albelda SM, June CH, Tanyi JL. Haas AR, et al. Among authors: tanyi jl. Mol Ther. 2023 Aug 2;31(8):2309-2325. doi: 10.1016/j.ymthe.2023.06.006. Epub 2023 Jun 12. Mol Ther. 2023. PMID: 37312454
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S, Bianchi V, Tanyi JL, Sarivalasis A, Missiaglia E, Pétremand R, Benedetti F, Torigian DA, Genolet R, Barras D, Michel A, Mastroyannis SA, Zsiros E, Dangaj Laniti D, Tsourti Z, Stevenson BJ, Iseli C, Levine BL, Speiser DE, Gfeller D, Bassani-Sternberg M, Powell DJ Jr, June CH, Dafni U, Kandalaft LE, Harari A, Coukos G. Bobisse S, et al. Among authors: tanyi jl. Nat Cancer. 2023 Oct;4(10):1410-1417. doi: 10.1038/s43018-023-00623-x. Epub 2023 Sep 21. Nat Cancer. 2023. PMID: 37735588 Clinical Trial.
CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?
Cutri-French C, Nasioudis D, George E, Tanyi JL. Cutri-French C, et al. Among authors: tanyi jl. Diagnostics (Basel). 2024 Apr 16;14(8):819. doi: 10.3390/diagnostics14080819. Diagnostics (Basel). 2024. PMID: 38667465 Free PMC article. Review.
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.
Hassan R, Butler M, O'Cearbhaill RE, Oh DY, Johnson M, Zikaras K, Smalley M, Ross M, Tanyi JL, Ghafoor A, Shah NN, Saboury B, Cao L, Quintás-Cardama A, Hong D. Hassan R, et al. Among authors: tanyi jl. Nat Med. 2023 Aug;29(8):2099-2109. doi: 10.1038/s41591-023-02452-y. Epub 2023 Jul 27. Nat Med. 2023. PMID: 37501016 Free PMC article. Clinical Trial.
A retrospective case series of Mohs micrographic surgery and interdisciplinary management of female genital skin cancers: Local recurrence rates and patient-reported outcomes.
Nugent ST, Raj LK, Latif NA, Cory L, Tanyi JL, Kovach SJ 3rd, Fischer JP, Fosnot J, Lin IC, Etzkorn JR, Shin TM, Giordano CN, Higgins HW 2nd, Walker JL, Miller CJ. Nugent ST, et al. Among authors: tanyi jl. J Am Acad Dermatol. 2023 Aug;89(2):301-308. doi: 10.1016/j.jaad.2023.02.050. Epub 2023 Mar 12. J Am Acad Dermatol. 2023. PMID: 36918082
Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study.
Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL. Wagner P, et al. Among authors: tanyi jl. Ann Surg Oncol. 2024 Apr 15. doi: 10.1245/s10434-024-15165-4. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38622456
ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from a Phase 2 Study.
Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL. Wagner P, et al. Among authors: tanyi jl. Ann Surg Oncol. 2024 May 9. doi: 10.1245/s10434-024-15307-8. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38722420 No abstract available.
H2Bub1 loss is an early contributor to clear cell ovarian cancer progression.
Ferrari AJ, Rawat P, Rendulich HS, Annapragada AV, Kinose Y, Zhang X, Devins K, Budina A, Scharpf RB, Mitchell MA, Tanyi JL, Morgan MA, Schwartz LE, Soong TR, Velculescu VE, Drapkin R. Ferrari AJ, et al. Among authors: tanyi jl. JCI Insight. 2023 Jun 22;8(12):e164995. doi: 10.1172/jci.insight.164995. JCI Insight. 2023. PMID: 37345659 Free PMC article.
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F. Wethington SL, et al. Among authors: tanyi jl. Clin Cancer Res. 2023 Aug 1;29(15):2800-2807. doi: 10.1158/1078-0432.CCR-22-2444. Clin Cancer Res. 2023. PMID: 37097611
80 results